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Abstract V a r i a t i o ni nt h eh u m a ng e n o m ei sam o s t
important cause of variable response to drugs and other
xenobiotics. Susceptibility to almost all diseases is deter-
mined to some extent by genetic variation. Driven by the
advances in molecular biology, pharmacogenetics has
evolved within the past 40 years from a niche discipline
to a major driving force of clinical pharmacology, and it is
currently one of the most actively pursued disciplines in
applied biomedical research in general. Nowadays we can
assess more than 1,000,000 polymorphisms or the expres-
sion of more than 25,000 genes in each participant of a
clinical study – at affordable costs. This has not yet
significantly changed common therapeutic practices, but a
number of physicians are starting to consider polymor-
phisms, such as those in CYP2C9, CYP2C19, CYP2D6,
TPMT and VKORC1, in daily medical practice. More
obviously, pharmacogenetics has changed the practices and
requirements in preclinical and clinical drug research; large
clinical trials without a pharmacogenomic add-on appear to
have become the minority. This review is about how the
discipline of pharmacogenetics has evolved from the
analysis of single proteins to current approaches involving
the broad analyses of the entire genome and of all mRNA
species or all metabolites and other approaches aimed at
trying to understand the entire biological system. Pharma-
cogenetics and genomics are becoming substantially inte-
grated fields of the profession of clinical pharmacology, and
education in the relevant methods, knowledge and concepts
form an indispensable part of the clinical pharmacology
curriculum and the professional life of pharmacologists
from early drug discovery to pharmacovigilance.
Pharmacogenetics of large single gene effects
and their clinical consequences
The science of pharmacogenetics originated from the
analysis of a few rare and sometimes serendipitously found
extreme reactions (phenotypes) observed in some humans;
these phenotypes were either inherited diseases or abnormal
reactions to drugs or other environmental factors. In 2008,
we are facing about 12 million single nucleotide poly-
morphisms in the human genome and a large amount of
other types of genomic variation. The impact of inherited
chemical individuality in metabolic enzymes has been well
known for more than 100 years [1], and still, the essence of
pharmacogenetics can be best illustrated with paradigmatic
case examples introduced below that show how inherited
variants in specific genes may impact reactions of human
beings to drugs and other environmental factors. Thus, the
first part of the review focuses on those polymorphisms
having a strong and reproducibly confirmed impact in
therapy with the drugs affected by the polymorphic proteins
(Table 1).
Genetic variation in drug-metabolizing enzymes
Glucose 6 phosphate dehydrogenase
A deficiency in the enzyme glucose-6-phosphase dehydro-
genase (G6PDH) was identified when about 10% of
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treatment with the antimalarial drug primaquine and other
drugs, whereas this problem was almost absent in White
Americans [2]. Electrophilic reactive metabolites of many
drugs can only poorly be detoxified in carriers of the x-
chromosomally inherited G6PDH deficiency [3]. Nowa-
days, more than 150 mutations causing G6PDH deficiency
are known. Because of this complex genetic background,
analysis of the phenotype (enzyme activity in red blood
cells) is still the preferred method of clinical diagnosis.
Fortunately, the disease is mostly self-limiting. Neverthe-
less, the drugs causing haemolysis should be avoided in
known carriers of the G6PDH deficiency.
A second lesson from the G6PDH issue is about inter-
ethnic differences in the risk–benefit ratio of drugs.
Haemolysis after primaquine was very rare in northern
European Caucasian populations, but it is a problem in 10%
or even much more of African and some Mediterranean
populations. These inter-ethnic differences in the popula-
tion frequencies of genetic polymorphisms are extremely
important in terms of the worldwide distribution of drugs.
Each company interested in worldwide marketing of a drug
is well advised to carefully study the pharmacogenetics
concerning inter-ethnic differences in the genes relevant for
drug disposition and pharmacodynamics [4]. And, of
course, these inter-ethnic differences have also to be
considered in pharmacovigilance, and adverse drug report-
ing (ADR) reporting should always ask for ethnicity.
Differences in frequencies of pharmacogenetic polymor-
phisms are a most important cause behind interethnic
differences in response to drugs [5].
The G6PDH story tells a third very important point –
important particularly for the legal, social and ethical
implications of pharmacogenetic diagnostics – namely, that
many pharmacogenetic variants have some good and some
bad sides for human health: carriers of the G6PDH
deficiency are at risk for drug-induced haemolysis. However,
they are protected from malaria to some extent, and it is well
known that the worldwide map of high prevalence of
G6PDH deficiency largely overlaps with malaria prevalence.
Butyrylcholine esterase
The muscle relaxants succinylcholine and mivacurium act
significantly longer in about 0.1% of patients compared
with the other 99.9%, and if physicians do not make
Table 1 Valid biomarkers: Pharmacogenetic polymorphisms with a consistently proven functional impact that should be regularly considered in
drug development and in drug treatment
Protein Abbreviation Selected substrates, ligands or drugs for which the polymorphism may be relevant
Glucose-6-phosphate
dehydrogenase
G6PDH Many drugs generating electrophilic reactive metabolites in human cells
Butyrylcholine esterase BCHE Mivacurium, procaine, succinylcholine,
N-acetyltransferase type 2 NAT2 Isoniazid, aromatic amines (occupational medicine and toxicology)
Cytochrome P450 2D6 CYP2D6 Amitriptyline, clomipramine, desipramine, doxepin, duloxetin, imipramine, nortriptyline,
trimipramine, paroxetin, venlafaxin; haloperidol, perphenazine; chlorpromazine,
perazine, promethazine, thioridazine, zyclopenthixol; aripiprazole, olanzapine;
amphetamine, atomoxetin; carvedilol, metoprolol, nebivolol, propranolol, timolol;
perhexiline; encainide, flecainide, mexilletine; ondansetron, tropisetron; codeine,
tramadol; tamoxifen
Cytochrome P450 2C19 CYP2C19 Omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole; voriconazole;
diazepam, alprazolam; amitriptyline, imipramine, doxepin; moclobemide; citalopram;
S-mephenytoin, phenytoin, primidone; clopidogrel; proguanil; cyclophosphamide,
teniposide
Cytochrome P450 2C9 CYP2C9 S-Warfarin, acenocoumarol, phenprocoumon; glimepiride, tolbutamide, glyburide,
nateglinide; losartan, candesartan, irbesartan; celecoxib, diclofenac, ibuprofen,
flurbiprofen, suprofen, naproxen, meloxicam, tenoxicam, piroxicam, lornoxicam;
phenytoin; fluvastatin; torsemide.
Thiopurine S-methyltransferase TPMT 6-Mercaptopurine, 6-thioguanine, azathioprine
Dihydropyrimidine dehydrogenase DPD 5-Fluorouracil, capecitabine
Uridin diphospho-glucuronic acid
transferase type 1A1
UGT1A1 Bilirubin, irinotecan
Vitamin K epoxide reductase VKORC1 Warfarin, acenocoumarol, phenprocoumon
Coagulation factor V FV Heparin, oral contraceptives, estrogens, SERMs
Organic anion transporting
polypeptide 1
OATP1B1 Almost all statins, methotrexate, repaglinide, rifampin, torsemide,
Major histocompatibility locus HLA-B HLA-B*5703 predicting Abacavir hypersensitivity
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even cause fatalities due to apnoea. This prolonged action
of succinylcholine and mivacurium is due to an inherited
lack of plasma cholinesterase, also known as butyrylcholine
esterase (BCHE) [6]. Although we could genotype patients
(i.e. analyse by molecular genetic methods) for the
underlying variants, measurement of the phenotype (the
BCHE activity) is still preferred because it is easy to
perform and is also informative on acquired liver disease.
N-acetyltransferase type 2
Acetylation is a phase II drug metabolism reaction in
several xenobiotics, including the anti-tuberculosis drug
isoniazid. About half of Caucasian populations are rapid
acetylators, whereas the other half are slow acetylators of
isoniazid [7, 8]. The responsible enzyme was identified as
arylamine N acetyltransferase and later specified as the type
2 enzyme (NAT2) [9]. There are several amino acid
substitutions in that enzyme, resulting in low protein
stability or low enzyme activity [10]. With the same dose
of the drug isoniazid, the 50% slow acetylators have high
blood concentrations and, most likely, a better antibacterial
efficacy, but they may have more adverse effects. The other
50%, the rapid acetylators, have low parent active drug
concentrations in their blood and tissues. Compared with
the slow acetylators, the drug is less effective in this latter
group, and this group probably has less adverse effects.
The acetylation polymorphism has been known for more
than 50 years, and many physicians are aware of it.
However, the NAT2 polymorphism is still not usually
considered in isoniazide prescriptions. This appears to be a
general feature of pharmacogenetic research findings:
knowing about an apparently medically significant genetic
polymorphism does not necessarily mean that physicians
start to use that knowledge to the benefit of the patient. The
latest clinical trial on whether or not isoniazide dose
adjustment according to NAT2 genotype really reduces
isoniazide hepatotoxicity and improves therapeutic efficacy
has not yet been completed [11], even 50 years after
discovery of the NAT2 polymorphism.
Cytochrome P450 2D6
A complete lack of cytochrome P450 2D6 (CYP2D6)
enzyme activity was first identified in 1975 and was based
on the appearance of exaggerated adverse effects in patients
receiving the drugs debrisoquine and sparteine [12, 13].
Following identification of the gene [14, 15], numerous
variants resulting in deficient activity, low activity and
ultra-rapid activity were identified [16–18] and, at least in
Caucasian populations, the CYP2D6 poor metabolizer
phenotype could be reasonably well predicted from the
genotype [19]. There is a wide range of enzyme activities
ranging from a complete lack of enzyme activity in the so-
called poor metabolizers (PM), to very low activity in
carriers of one deficient and one low-activity allele, to
intermediate activity in heterozygous carriers of one active
and one deficient allele, to high activity in the extensive
metabolizers (EM) and up to extremely high activity in the
ultra-rapid metabolizers (UM).
The clinical impact of the CYP2D6 genotype depends on
whether the drugs are bioactivated by CYP2D6 or
inactivated. Some of the substrates of CYP2D6 are
summarized in Table 1 [20]. Most of these are metabolized
to inactive metabolites. However, there are notable excep-
tions of drugs bio-activated by CYP2D6, such as codeine,
tramadol, tamoxifen and encainide. It is difficult to
understand why the extensive variation of CYP2D6 is not
yet regularly considered in medicine. Dose-dependent
adverse drug effects and thus the quality of life, but also
survival of breast cancer patients receiving tamoxifen may
depend on this enzyme [21]. In order to promote further
concrete application of and research on CYP2D6 pharma-
cogenetic genotyping in medical practice, dose-adjustment
recommendations based on available published pharmaco-
k i n e t i cd a t ah a v eb e e nd e r i v e d( s e e[ 22–24]). These
CYP2D6 genotype-based dosage recommendations illus-
trate how individualized medicine may work in daily
medical practice.
Cytochrome P450 C19
A complete lack of the enzyme CYP2C19 was first
described to result in the slow elimination of the S-
enantiomer of the antiepileptic drug mephenytoin [25].
CYP2C19 metabolizes all currently marketed proton pump
inhibitors, several antidepressants and the antimycotic drug
voriconazole. There is absolutely no activity of this enzyme
in about 3% or Caucasians and in about 20% of Asian
populations. This is due to a few variants; in Caucasians,
most inter-individual variation in function is explained by
the variant CYP2C19*2 [26], but worldwide a number of
other variants may have to be considered, in particular
CYP2C19*3 [27, 28]. A co-dominant mode of inheritance
has been consistently seen, and thus heterozygous carriers
of CYP2C19 have about half of the activity of the
homozygous carriers. A promoter variant has been de-
scribed recently, termed CYP2C19*17, resulting in very
rapid metabolism [29]. The medical impact of CYP2C19
depends on whether the drugs are converted to active or
inactive metabolites. Tricyclic antidepressants are converted
by CYP2C19 to similarly active metabolites. The prodrug
clopidogrel, a most important antithrombotic agent, is
bioactivated partially via CYP2C19 [30]. It has not yet
been unequivocally determined to what extend routine
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dogrel might reduce trombosis on the side or bleeding on
the other side. However, the proton pump inhibitors are
deactivated, and a significant improvement of therapy with
proton pump inhibitors may be obtained by genotyping for
CYP2C19 [31].
Cytochrome P450 2C9
A genetically determined low activity of CYP2C9 is long
known from tolbutamide and phenytoin metabolism. In
Caucasians, this aberration is mostly due to two frequent
amino acid substitutions in the enzyme, termed CYP2C9*2
and CYP2C9*3 [32, 33]. Worldwide, a number of other
variants have also to be considered [34, 35]. The CYP2C9
polymorphisms are relevant for the efficacy and adverse
effects of numerous nonsteroidal anti-inflammatory agents
[36–39], sulfonylurea antidiabetic drugs (see [40–43]) and,
most critically, oral anticoagulants belonging to the class of
vitamin K epoxide reductase (VKORC1) inhibitors [44].
Numerous studies have shown that the CYP2C9 polymor-
phism should be considered in warfarin therapy, and practical
algorithms how to consider it in therapy are available [45].
Thiopurine S-methyltransferase
The autosomal co-dominant genetic polymorphism in
thiopurine S-methyltransferase was detected about 30 years
ago and is a major determinant of the efficacy and toxicity
of 6-mercaptopurine, 6-thioguanine and azathioprine [46].
Amino acid substitutions Ala18Pro, Ala154Thr and the
combination of Ala154Thr with Tyr240Cys, known as
TPMT alleles *2, *3C and *3A, respectively, have allele
frequencies of 0.4, 0.2 and 4.4% in Caucasian populations,
respectively, and explain most of the low thiopurine S-
methyltransferase activity phenotypes. The frequency of the
carrier of two inactive TPMT alleles is low – 0.3% in
Caucasians populations. Nevertheless, due to the potentially
fatal consequences of ignoring TPMP deficiency [47], the
identification of such individuals and of the about 10% of
heterozygous carriers is recommended, even in the drug
label [48]. Although recommended, still less than 12% of
the oncology, haematology and paediatrics department in
the EU regularly performed TPMT genotyping or pheno-
typing before administrating thiopurine drugs, and 53% did
not perform the test at all in 2005 [49].
Dihydropyrimidine dehydrogenase
The enzyme dihydropyrimidine dehydrogenase (DPD) is
rate limiting in terms of the catabolism of uracil and
thymine and converts 5-fluorouracil (5-FU) to the inactive
dihydrofluorouracil. In humans, more than 80% of admin-
istered 5-FU is degraded via DPD. Independently from 5-
FU therapy, a deficiency of DPD may be associated with
severe neurological deficits, but there is no simple
genotype–phenotype relationship [50]. Deficient or very
low DPD activity may result in severe adverse effects from
5-FU [51] or capecitabine. In some clinics, patients are
routinely tested for one relatively frequent IVS14+1G>A
splice-site polymorphism [52]. However, there are a
number of other rare genetic variants in DPD, and only a
small fraction of patients with severe 5-FU toxicity have
that IVS14+1G>A splice-site variant. We are not aware of a
study clarifying whether 5-FU dose reduction or choosing
alternative drugs would be the better choice.
Uridin diphospho-glucuronic acid transferase type 1A1
UGT1A1 is the bilirubin glucuronidase, and benign hyper-
biliribinema, known as Gilbert–Meulengracht disease, is
mostly explained by a promoter variant with lower
transcriptional activity of (TA)7 carriers compared with
(TA)6 carriers [53]. UGT1A1 also contributes to the
glucuronidation of drugs and, in particular, to the glucur-
onidation of the topoisomerase inhibitor irinotecan. Con-
sideration of the UGT1A1 genotype is recommended in the
irinotecan drug label [48]. The UGT1A1 genotype appears
to predict an increased risk of severe (grade 3 and grade 4)
haematotoxicity in irinotecan high-dose schemes [54]. The
full impact of this UGT1A1 polymorphism is apparently not
yet known. In addition, as several other drug also have a
potential to contribute to glucuronidation, there may be so-
called metabolic crosstalk, i.e. the low bilirubin glucuroni-
dation capacity may result in competitive inhibition of the
thus higher unconjugated bilirubin with several drugs at the
efflux transporters.
Genetic variation in drug transport
Only in the past 15 years have pharmacologists became
fully aware of the impact of transmembrane drug trans-
porters on the uptake of drugs from the gut into the human
body and from the circulation into the target tissues and
into the metabolizing and eliminating organs. This carrier-
mediated transmembrane transport becomes particularly
important in molecules with larger molecular diameters
[55]. To understand the pharmacokinetics of drugs, even in
a single cell, phase 0 (influx transport), phase 1 (mostly
oxidative or reductive biotransformation), phase 2 (con-
jugations) and phase 3 (efflux transport) have to be
considered. There are only a few drugs for which all of
the transporter proteins relevant from uptake to final
elimination of the metabolites from the body are fully
identified. When the entire multi-organ organism is consid-
ered, the situation is even more complex. The transporters
136 Eur J Clin Pharmacol (2008) 64:133–157act as the most important determinants of barriers between
body compartments, such as the blood brain barrier.
Elucidation of these minimally four phases (0, 1, 2, and
3) of pharmacokinetics of a drug in experimental or clinical
studies may be a first step towards a complete system
biological understanding of the pharmacogenetics of a drug.
One of the human multiple drug resistance (MDR)
conferring transporters, MDR1, was among the first trans-
porters extensively screened for genetic polymorphisms. A
number of variants having some functional impact have
been identified [56]. However, subsequent studies often
resulted in discrepant results [57, 58] so that polymor-
phisms in MDR1 cannot yet be considered as valid
biomarkers, because it is not clear how exactly these
polymorphisms should be considered in drug therapy or
drug development. There are numerous non-synonymous
(i.e. protein sequence changing) polymorphisms in MDR1
and in other efflux transporters, such as breast cancer
resistance protein (BRCP) and in the multidrug resistance-
associated proteins (MRPs) (Table 2).
The drug transporter organic anion-transporting polypep-
tide OATP1B1 (synonym OATP-C) is primarily expressed in
hepatocytes and catalyses the influx-transport of many
organic anions (Table 2). A number of polymorphisms have
been found [59], and two variants have frequently been
analysed clinically: the highly active Asn130Asp variant and
the low-active Val174Ala variant [60]. Since OATP1B1
typically catalyses the influx transport of organic anions and
CYP2C9 typically metabolizes such organic anions, epistatic
effects between OATP1B1 and CYP2C9 may become an
important focus of molecular and clinical pharmacological
research [61]( T a b l e2). Renal tubular secretion of organic
anions is mediated by organic anion transporters OAT1,
OAT3 and OAT4, but polymorphisms in these transporters
can explain only a relatively small fraction of the interindi-
vidual pharmacokinetic variation of the presumed substrates
of these transporters [62].
Many drugs belonging to the organic cations can be
transported into the cells by the organic anion transporters
OCT1, OCT2 and OCT3. These three transporters differ
particularly in their tissue distribution. OCT1 may be
relevant for hepatic uptake of the cationic metformin into
the hepatocyte. While little variation in metformin plasma
pharmacokinetics was explained by polymorphisms in
OCT1, polymorphisms in that gene appeared to modulate
appeared to modulate the access of metformin to its target
sites in the liver cell [63]. Although these data are
preliminary because of the small sample size, the results
illustrate an important point concerning drug transporter
pharmacogenetics: while the plasma compartment is a con-
venient one for pharmacokinetic analyses, it is often not the
right compartment to study clinically relevant effects of
drug transporter polymorphisms. To understand the medical
impact of polymorphisms in drug transporter genes, drug
concentrations have to be analysed in the effect compart-
ments.Alternatively,one maylookforandusevalidsurrogate
tissues or surrogate cells of the true effects compartments.
Genetic variation in drug targets
Vitamin K epoxide reductase
Only recently has the gene coding for vitamin K epoxide
reductase (VKORC1) been identified [64]. A certain
haplotype in VKORC corresponds to low expression and
high sensitivity to the oral anticoagulants warfarin, aceno-
coumarol and phenprocoumon (dicumarol) [65]. CYP2C9
plus VKORC genotyping may soon become a clinical
routine in patients going to receive oral anticoagulants such
as warfarin or acenocoumarol.
Factor V
Coagulation factor V is a cofactor of the prothrombin-
activating complex, and the arginine560-to-glutamine sub-
stitution in factor V, known as the Leiden variant [66],
results in higher protein stability and thus in higher
coagulation compared with the arginine560 wild type. In
drug therapies increasing the risk of thrombosis, the factor
V polymorphism is an important modulator of that risk.
Table 2 Potential impact of polymorphisms in drug transporters and drug-metabolizing enzymes depending on the chemical nature of the drug
Molecular characteristics Examples of typical transporters (genes) Typical enzymes
Large amphipathic, mostly
apolar
MDR1 (ABCB1), BCRP (ABCG2), MRP1 (ABCC1),
MRP2 (ABCC2)
CYP3A4, CYP3A5
Organic anionic OATP1A2, OATP1B1, OATP2B1, OAT1, OAT2,
OAT3, OAT4
CYP2C9
Organic cationic OCT1, OCT2, OCT3, OCTN1, OCTN2 CYP2D6
Amino acid and peptide
derivatives
LAT1, LAT2, TAT1, PepT1, PepT2 Numerous enzymes of amino acid metabolism
Nucleoside analogues hCNT1, hCNT2, hCNT3, hENT1, hENT2, hENT3 Numerous enzymes of nucleobase, nucleoside and
nucleotide metabolism
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contraceptives is significantly increased in carriers of the
factor V Leiden variant. Molecular genetic analysis for that
variant has become a routine part of the clinical differential
diagnosis of venous thrombosis. Routine genotyping before
clinical medication with oral contraceptives, oestrogens or
selective oestrogen receptor modifiers. such as tamoxifen or
other drugs increasing risk of thrombosis, is currently not
recommended on a routine basis [67]. However, this
recommendation not to perform routine factor V pharma-
cogenetic testing at present depends on several social,
medical and economic circumstances and, consequently, the
recommendation not routinely to genotype preemptively
may change in the coming years.
Genotyping for the factor V polymorphism has been
introduced into the routine practice of drug development: In
phase II clinical drug trials (trials in which the benefits of
the drug have not yet been proven) with drugs having a pro-
thrombotic risk, all carriers of the factor V Leiden variant
should excluded for safety reasons. This is an example of
how pharmacogenetic genotyping may improve safety of
volunteers in early clinical drug development.
Beta adrenergic receptors ADRB1 and ADRB2
There are genetic polymorphisms in the gene coding for the
beta1 adrenergic receptor (ADRB1) and in that coding for the
beta2 receptor (ADRB2). In ADRB1, a Ser49Gly variant
may be associated with enhanced agonist-induced down-
regulation, whereas a Gly389Arg variant was found to bring
about a fourfold higher agonist stimulated signal transduc-
tion to the Gs protein [68, 69] compared with the Gly allele.
Recent data have shown that the effects of the ADRB1
polymorphism may differ depending on the specific beta-
blocker used [70]. There is extensive clinical data on these
two ADRB1 polymorphisms and hypertension, response to
beta-blocker treatment, susceptibility to heart failure and
response to treatment. However, few data are consistent
between all studies [71] and, therefore, according to the
understanding of the authors, the ADRB1 data are not yet
clear enough to be considered as a valid biomarker (Table 1)
in routine drug therapy and drug development.
Also in the Beta2 receptor gene, ADRB2, there are two
frequent variants resulting in Arg16Gly and Glu27Gln
amino acid substitutions. Despite early promising results
showing that these variants may modify the risk for
bronchogenic asthma, other diseases or the response to
therapy, data from many subsequent studies have been
inconsistent [72].
Polymorphisms in many drug receptors have been
studied in the past 15 years, and the different groups have
frequently come to divergent conclusions. However, not all
presumed discrepancies are real discrepancies. There are
different levels of pharmacogenetic and genomic research
(Table 3), starting with molecular research (level 1), then
going into different levels of translational research and
finally ending with clinical therapeutic (level 4) or clinical
diagnostic (level 6) research. A genetic variant with a
proven functional impact at low-complexity level 1 may not
have any clinical impact at all, or only have clinical impact
under certain conditions to be identified. On the other hand,
we will not be satisfied with mere association research on a
variant apparently having a clinical impact as long as the
molecular effects are obscure. While in therapeutic research
clinical endpoints (level 4) are indispensable in deciding
upon the value of a given therapy, in pharmacogenetic and
genomic research often less complex systems (levels 2 and
3) may be preferable, at least at the beginnings of research.
Table 3 Levels of research in pharmacogenetics and genomics: From well defined molecules to complex biological and social interactions
Level Focus on Complexity of the
studied system
Some possible confounders to be considered
1. Single molecule molecular Low, well defined
2. Cell biology Moderate Cell type, cell passage number, culture medium, substrate and
substrate concentrations
3. Human clinical endophenotypes High Dose, ethnicity, duration of exposure, age, gender, co-
medication
4. Response of humans to drugs (efficacy
and adverse events)
Very high Dose, ethnicity, type of disease, age, gender, other inclusion
and exclusion criteria
5. Human disease susceptibility Extremely high Types and duration of exposure to environmental factors
6. Research on value of clinical
pharmacogenetic diagnostics
7. Economic and ethical aspects of
pharmacogenetics
Dependent on the respective health insurance system and drug
and health service costs
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While most of the polymorphisms introduced above may be
associated with type A (aggravated, overdose-like) adverse
drug reactions, type B (bizarre, idiosyncratic, mostly
allergic) adverse drug reactions may be explained by
polymorphisms in genes of the major histocompatibility
complex. Severe (and in some cases fatal) allergic reactions
to the HIV nucleoside analogue drug abacavir have been
explained by the HLA-B*5701 allele, and a HLA-B*5701,
HLA-DR7, and HLA-DQ3 haplotype even had positive and
negative predictive values of 100 and 97%, respectively
[73], strongly advocating routine testing before abacavir
prescription. Such a testing may not only be medically
needed, but it may also be cost-effective [74].
The concept of individualized drug therapy
Pharmacogenetics of drug target concentrations
Individualized drug therapy means that the choice of the
drug and the choice of drug dosing regimens are selected
based on the patient_s individual requirements. In addition,
the requirement for extra monitoring or for add-on therapies
may depend on individual characteristics of the patient,
including pharmacogenetic data. Optimal drugs and drug
doses depend on age, gender, body weight, co-morbidity,
organ functions, drug–drug interactions, lifestyle, culture,
ethnicity and pharmacogenetic data. All of these data and
particularly their combinations may be so variable that in
theory there should rarely be two patients for whom exactly
the same medications may be optimal.
In the past 50 years clinical pharmacogenetics has mostly
evolved as the pharmacogenetics of blood concentrations,
with the assumption that blood concentrations mirror the
concentrations at the target sites. In several therapeutic areas
this concept has proved to be therapeutically valuable; for
example, the monitoring of blood concentrations of amino-
glycosides or immunosuppressive drugs has resulted in the
therapy with these drugs becoming significantly more safe
and efficient. More than 50% of all adverse drug reactions
are dose-related type A reactions, so that an understanding of
the causes behind individually wrong blood concentrations
of drugs may significantly reduce adverse drug reactions.
However, target concentrations in many instances are not the
plasma concentrations but concentrations in specific tissues
at specific target organs. One example is the recent study on
OCT1 variants and metformin pharmacokinetics and dynam-
ics [63]. Apparently the effect of functional OCT1 variants
was not seen in the blood concentrations [63], but the
transporter variants had some impact on effects, indicating
that they had an effect on the transfer of the drug to its target
compartment, the liver.
Drug effects and therapy recommendations
To the best of our knowledge, in 2007, phenotyping or
genotyping for pharmacogenetic polymorphisms had a firm
regular place in only a few hospitals or doctor’s offices.
However, in a larger number of institutions, genotyping is
sometimes performed in some patients with adverse drug
events or in patients refractory to therapy [75, 76]. As with
any laboratory test, pharmacogenetic genotyping does not
make much sense unless clear rules are available so that
practical conclusions can be drawn from the results of the
genotyping tests. Based on the bioequivalence concept to
achieve similar blood concentrations in all patients, it is
possible to calculate preliminary doses that take genotype-
dependent differences in bioavailability and drug clearance
into consideration [77]. These recommendations follow
bioequivalence concepts generally accepted by regulatory
authorities – that is if two brands of a drug result in blood
concentrations which do not significantly differ, the two
brands can be considered to be equivalent. Similarly, it is
possible to find equivalent doses for different pharmacoki-
netic genotypes. Figure 1 illustrates up to how much such
doses may have to be adjusted to achieve equivalent drug
concentrations.
Of course, in prodrugs bioactivated via a polymorphic
enzyme, such as codeine, tramadol, tamoxifen, encainide,
clopidogrel and others, the relationship reverses: in these
drugs, deficient or very slow metabolizers might better
receive alternative drugs, intermediate metabolizers might
receive slightly higher than average doses and ultra-rapid
metabolizers should receive lower than average doses
instead of higher than average doses [78].
Such a concept of pre-emptive pharmacogenetic diag-
nostics and dose adjustments as illustrated in Fig. 1 needs
evidence-based verification by controlled diagnostics trials.
There are some controlled trials showing that proton pump
inhibitors should be dosed according to CYP2C19 geno-
type [31]. Data supporting the concept of preemptive NAT2
genotyping in therapy with isoniazid date back 50 years [7].
Nevertheless, we still need trials on NAT2 genotyping in
the treatment with isoniazid [11] since theoretical consid-
erations and some early clinical data suggest both pros and
cons from rapid and slow acetylation in terms of the
problem of hepatotoxicity. There are initial data confirming
that prospective genotyping for CYP2C9 may make therapy
with warfarin safer than current therapy as usual [80]. At a
first glance it is surprising that pharmacogenetics can
improve therapy with oral anticoagulants. There is a good
monitoring for oral anticoagulants. However, if physicians
are aware in advance who is at a particular risk of over-
anticoagulation, they can select individual loading doses.
More trials in this area are ongoing to test the concept that
prospective genotyping of CYP2C9 and VKORC1 in
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safety of the patients. These trials are particularly demand-
ing when it is taken into account that in some groups the
annual risk for severe bleeding may be as high as 13%,
such as in the subgroup of the elderly, during the first year
of treatment [81]. The design of such trials is conceptually
and ethically very demanding because we know beforehand
that genotyping can prevent fatalities.
Even before pharmacogenetic diagnostics is introduced
into general medical practice, people are asking whether or
not pharmacogenetic diagnostics is cost-effective. Such an
evaluation of economics only makes sense after the medial
value has been demonstrated. First evaluations on the
economics have appeared and indicate that pharmacoge-
netic diagnostics may be cost-effective [82]. It was
calculated that in psychiatric diseases, therapeutic problems
arising from extreme (deficient or ultra-rapid) biotransfor-
mation may cause between 4000 and 6000 US$ additional
costs in patients having these genotypes [83].
The search for disease risk genes
Pharmacogenetics primarily deals with the therapeutic
effects and the adverse effects of humans to drugs, poisons
and other types of chemicals and environmental factors.
However, soon after the field of pharmacogenetics emerged,
this scope was broadened and the genetic polymorphisms
were extensively studied, not only in relation to known
specified exposures but also as susceptibility factors for
diseases in general. In many of these studies the disease
initiating conditions were not known. In parallel, the
functional nature of the genes considered in pharmacogenetic
research broadened from drug-metabolizing enzymes to
almost all other classes, such as drug transport, DNA-repair,
cell-cycle regulation and signal transduction [4]. The overall
number of publications studying pharmacogenetic polymor-
phisms in relation to disease risk exceeds several-fold those
studying the polymorphisms in relation to response to drugs,
and it is not possible to give in this review a meaningful
summary of that research on the hundreds of candidate genes
as disease susceptibility factors. Still, it might be interesting
to analyse this research systematically in order to improve
future strategies in pharmaocogenetic and genomic research.
Also, almost all recent genome-wide screens did not focus
on the response to drugs but on the identification of
genotypes predisposing to certain multifactorial and poly-
genic diseases.
Chemical toxicology and carcinogenesis
Reactions in foreign compound metabolism may result in
biologically or chemically active compounds or in inactive
compounds and, therefore, the individual human set of
toxifying and detoxifying genes may determine our risk for
disease. Enzymes such as the acteyltransferases, glutathione
S-transferases M1 and T1, paraoxonases, myeloperoxidase
have protein coding variants resulting in a broad range of
activities between a complete lack of activity and extremely
high activity depending on the enzyme and the individual
genotype. Therefore it is evident that such genetic variants
Fig. 1 Preemptive genotype-based dose adjustment. A 100% of the
dose would correspond to the currently recommended dose accord-
ing to the drug information to prescribers. Based on pharmacokinetic
data analyses ,one might recommend for some patients lower or
higher doses compared to the standard doses (see [77, 79]f o rm o r e
details)
140 Eur J Clin Pharmacol (2008) 64:133–157may play a role in chemical carcinogenesis, in chemically
induced neurodegenerative disease or in chemically in-
duced endothelial damage and arteriosclerosis. The follow-
ing two examples, CYP2D6 and GSTM1, may serve to
illustrate some of the general points and problems, which
are also illustrated in Fig. 2.
Soon after the discovery of the CYP2D6 polymorphism,
scientists started investigating polymorphisms as a risk
factor for lung cancer. The motivation to do this research
can be understood: there are big interindividual differences
in susceptibility to lung cancer, and scientists at those times
knew that all cytochrome P450 enzymes can bioactivate
procarcinogenes. Indeed, the results of one of these studies
indicated that rapid metabolizers have a significantly
increased risk [84]. A number of other studies could not
confirm this data absolutely [85], and some could, but only
in subgroups. However, at the present time, there are doubts
that CYP2D6 plays a significant role in lung cancer. There
are some thoughts on carcinogens that might be bioacti-
vated by CYP2D6, but there is no proof that these are the
crucial ones in lung cancer. Nowadays one would like to
see large confirmatory studies proving the impact of
CYP2D6 in lung cancer.
Glutathione S-transferase M1 is a phase II enzyme
involved in the detoxification of several polycyclic aromatic
hydrocarbons. About 50% of the Caucasian population have
a complete lack of the enzyme due to a large genomic
deletion [86]. This provided the basis for studying this
enzyme in relation to lung cancer risk, and some studies
indeed described an increased risk in individuals lacking this
enzyme, but no such effects could be found in a sufficiently
powerful meta-analysis [87]. In addition, initial genome-
wide analyses on lung cancer risk factors have not identified
this lack of a detoxifying enzyme as a risk factor [88].
Mastering a mass of genomic variation
The vast extent of inherited variation in the human genome
only recently became apparent after almost the complete
DNA sequences of the human genome became available.
One can extrapolate [89] that very soon several human
individuals will be entirely sequenced and that this will
provide a more clearly understanding of inter-individual
variation in human genomes. At the present time about 12
million single nucleotide polymorphisms (SNPs) have been
identified in the human genome [90–92]. In addition, there
are probably more than 100,000 insertions and deletions.
There is also a large class of genetic variations summarized
as variable number of tandem repeat polymorphisms
(VNTR) (Table 4). These include variable numbers of
dinucleotide repeats, such as a variable number of TA in the
TATA box in the core promoter of bilirubin glucuronyl-
transferase UGT1A1 and larger repeat units, such as the 16
amino acid (48 bp) repeat in the dopamine D4 receptor
[93]. Only recently we have learned that there are at least
1500 large genomic segments occurring interindividually in
variable copy numbers [90–92]. The total amount of
Research on disease susceptibility
Research on drug therapy response 
Usually: Multiple mostly unknown interacting environmental and genetic factors 
Usually: Well-documented therapies with chemically defined drugs and 
well-documented doses 
? ? ?  ?
? 
?
? 
? 
• Drug A, dose a 
• Drug B, dose b 
• ... 
Genes 
Genes 
Genes 
Genes 
Response
ADR  Genes  
Clinical 
disease 
→→
Fig. 2 Differences between pharmacogenomic studies on disease
susceptibility (upper part) and drug response (lower part). In the
pathogenesis of diseases, mostly multiple endogenous factors (indicated
by the question marks, because these exogenous factors are mostly not
well documented) interact at multiple time points with one gene or
multiple genes. On the other hand, in drug therapy studies, the exposure
(i.e. type and dose of drug, optimally even plasma concentrations of the
drug to differentiate between pharmacokinetic and pharmacodynamics
sources of variation) of the drugs are known. In theory, this should make
the identification of genes modulating response to the drugs easier than
the identification of genes responsible for the development of diseases.
ADR Adverse drug reaction
Eur J Clin Pharmacol (2008) 64:133–157 141inherited epigenetic variation may even be larger, and at
least 20% of all genes are differentially methylated in the
promoter regions or in the coding regions [90–92].
A central question behind this mass of genomic and
epigenomic variation is to identify what is biologically and
medically relevant (Fig. 3). Polymorphisms affecting gene
expression may reside anywhere – from directly in the core
promoter, a few hundred or several ten thousands of bases
upstream (in 5’ direction) or even downstream in the intron
and untranslated regions (UTRs) of the gene. Considering
that the primary transcript is the entire region between the
transcriptional start and the 3’ end of the transcript, all
polymorphisms in this segment may affect splicing.
Interestingly, there is even more than one transcriptional
start point for more than half of all genes, and such
transcriptional start points may very depending on the
tissues where the gene is expressed [94]. Polymorphisms in
the coding region may be non-synonymous – i.e. resulting
in amino acid substitutions – or they may be synonymous.
The latter may still be functionally relevant by affecting
mRNA stability or by affecting protein transcription
because tRNAs for the different synonymous codons are
not equally frequent in cells, and such different codon
usage may not only result in differences in translational
efficacy but, based on the example of an apparently
functional polymorphisms in p-glycoprotein, it has been
discussed that such polymorphisms may even result in
differences in protein structure [56, 95].
Copy number variation: CYP2A6, CYP2D6, GSTM1,
GSTT1 and 1500 other such sites
Deletions or duplications of large genomic fragments
(ranging in size from 1 kb to more than 100 kb) were
thought to be specific for the unstable tumor genomes and
more an exception in the genome of healthy non-malignant
cells. This understanding had to be revised after a series of
genome-wide analyses using SNP-microarrays and com-
parative genome hybridization analyses as well as in in
silico comparisons of genomes from different individuals,
which revealed more than 1400 deletions or duplications
covering 12% of the “healthy” human genome sequence
[92, 96–101]. This class of genetic polymorphisms, called
copy number variations (CNV), represents stable genetic
variation that undergoes Mendelian segregation as SNP,
InDel or VNTR polymorphisms. Actually, such CNV
Table 4 Types and amount of interindividual variation in the human genome
Genetic change/
variation
Abbreviation Description Frequency in human
genome
Single nucleotide
polymorphism
SNP Typically two different nucleotides (biallelic SNPs) at one defined position, but
more rarely also triallelic variants occur
12,000,000
Deletions/
Insertions
InDel Deletions (or insertions, depending on the allele frequencies) of between 1 to
1000 nucleotides. More frequent are deletions of one or three basepairs.
> 1,000,000
a
Varying number of
tandem repeats
VNTR Microsatellites, also termed short tandem repeat (STR) polymorphisms are
typically tandem repeats of two, three or four nucleotides, but repeats up to
ten nucleotides in length may also classified in this group
> 500,000
a
Minisatellites are VNTR polymorphisms in which 10–100 nucleotides are
repeated in variable numbers. Repeated segments often do not have exactly
identical sequences.
VNTRs with larger repeat units (100–1000 bp) are termed satellites.
Copy number
variation
CNV Inheritable deletion or multiplication of DNA segments larger than 1 kb.
Currently, about 1500 CNVs distributed through all chromosomes are known;
estimated to cover 12% of the human genome length.
> 1500 loci covering
12% of the genome
Epigenetic and somatic variations of the human genome
Cell karyotype and somatic
mutations
Typically in tumours where DNA recombination and repair machineries are
damaged, but also in some inherited diseases.
DNA methylation Methylation of the cytosine residues of CpG repeats (known as CpG islands) of
the DNA transmitted through generations. Methylation of CpG islands
located in the promoter or the 5-untranslated region of the genes causing
down-regulation, whether methylation in the gene coding regions can cause
up-regulation of the gene expression.
> 20% of all genes
aEstimates based on databases and publications (e.g. [89])
142 Eur J Clin Pharmacol (2008) 64:133–157polymorphisms are not so new in pharmacogenetics. Large
gene deletions duplications or higher amplifications are
well known for the CYP2D6 gene [18], for CYP2A6 and
for glutathione S-transferases (GSTs) M1 and T1 [86, 102].
The recent findings, however, demonstrate how common
such huge genomic variations are – a fact we were not
aware of previously – and it may even be argued that those
1500 CNV polymorphisms have a similarly large effect on
disease susceptibility or response to drugs as the 12 million
SNPs. Before addressing this systematically, we will have
to acquire precise and affordable analytical methodologies
for this type of genomic variation, since current high-
density 500-k or 1000-k microarray methods or quantitative
PCR methods specific for only one locus, such as those
developed for CYP2D6 or the GSTs [103, 104], still have a
number of limitations.
Pharmacogenomics beyond genomic germ-line inheritance
Acquired genomic variation
Further complications in pharmacogenetics arise due to
chromosomal aberrations and variable numbers of chromo-
somes (aneuploidy) in tumour cells. The non-maligned cells,
such as peripheral blood cells, which are commonly used to
obtain genomic DNA for the pharmacogenomics analyses,
possess diploid genomes. In tumour cells, however, aneu-
ploidy and chromosomal aberrations are common. This
complicates the prediction of phenotypes by usual genotyp-
ing procedures not using DNA from the tumours themselves.
This was shown in leukemia cells where an additional
chromosome containing the wild-type TPMT allele had
significantly lower accumulation of thioguanine nucleotides
or methotrexate polyglutamates, respectively [105]. Still, the
TPMT genotype determined in the healthy non-malignant
cells was associated with the response to mercaptopurine in
the early course of childhood ALL [106].
Genomics versus epigenomics
We (scientists and physicians engaged in pharmacogenetics
and genomics) have learned and repeatedly taught the
following: analyzing inherited genetic variation has the big
advantage that analysing the genome of one cell of an
organism provides reliable information on all the other cells
independent of age, tissue localization or environmental
factors. However, there are somatic cell mutations as well as
tissue-specific epigenetic effects, such as DNA methylation,
histone modification or micro-RNA expression, that signifi-
cantly and constantly can change the pattern of gene
expression of the cell. Such changes can significantly modify
drug efficacy or initiate adverse effects and, therefore, they
have to be taken into account in future clinical pharmacology
[107]. The simple lesson is that clinical pharmacology will
have to learn about and do research in the fields of
epigenomics and the worlds of small regulatory RNAs.
Interesting first insights have appeared in relation to cancer
chemotherapeutic drugs.
Fig. 3 Some of the possible functional effectsofgeneticpolymorphisms
[single nucleotide polymorphisms (SNPs), small insertions–deletions
(InDels), varying number of tandem repeats (VNTRs)] depending on
their localization in the genome. Upper part a hypothetical typical
human gene is shown with the exons as black boxes and the 5’ and 3’-
translated but not transcribed segments (untranslated regions, UTRs) as
open boxes
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The expression of the gene coding for dihydropyrimidine
dehydrogenase (DPD) is a good marker for DPD deficiency
and 5-FU toxicity. Apparently inherited genetic polymor-
phisms can explain only about one-third of the DPD
enzyme deficiency and 5-FU toxicity [108, 109], but
methylation of the DPYD promoter may account for a
significant part of the as-yet unexplained low DPD activity
both in tumour and healthy tissues, which is so important
for adverse events from and the response to the drug [110–
113]. Another example is the tumour-specific hypermethy-
lation of MGMT. MGMT is a DNA-repair enzyme and its
inactivation by changes in its methylation pattern can result
in increased sensitivity of the tumour for alkylating drugs
such as cyclophosphamide or carmustine [114].
RNAi siRNA and miRNA
The phenomenon of RNA interference (RNAi) regulating
gene expression was first described in the nematode
Caenorhabditis elegans [115]. In vertebrates and humans,
small 19- to 22-nucleotide-long micro-RNA (miRNA)
molecules are present in almost all cells; these are genetically
encoded and regulate sequence-specific gene expression both
by translational repression and mRNA degradation in normal
development and cell regulation and in tumourigenesis [116,
117]. A SNP in the 3′-UTR of the AGTR1 gene (rs5186)
was found to affect the miRNA-155 recognition site and
changes its silencing effects [118]. This result illustrates that
genetic variations not only in the coding regions, promoters
or intron-splicing sites of the genes but also in their 3’-UTRs
could be of functional relevance mediated by miRNAs. Also,
14 of the human genome CNV regions harbor 21 of the
known human miRNAs, which results in the deletion of
entire miRNA genes [100]. There is, however, no data on
phenotypic changes in the carrier of these CNVs.
Artificial 21- 22-bp-long double-stranded RNA mole-
cules, called small interfering RNAs (siRNAs), are used to
experimentally knock down gene expression [119]. RNAi is
of general interest as a tool for analysing gene function.
siRNAs have been shown to be able not only to specifically
silence gene expression but also to do that in allele-specific
manner even if the difference is a single base of a SNP
[120–123]. This may allow genotype-specific therapy
where a disease allele can be specifically targeted by
siRNA if we can solve some practical problems [124].
Molecular markers guiding drug therapy
Therapy guided by molecular markers is becoming more
and more of a medical routine. The status of breast cancer
in terms of the expression of the HER2/neu and the
oestrogen receptor determines therapy with agents specif-
ically targeting the HER2 or the estrogen receptor (ER),
namely trastuzumab (Herzeptin) and tamoxifen. The rec-
ommended tests for HER2 analysis are protein-based using
immunohistochemical assays (IHC) or the direct detection
of HER2 gene amplification using the fluorescence in situ
hybridization (FISH) technique [125, 126]. In the case of
HER2, the qPCR assays are available both for the detection
of HER2 amplification at the chromosome level and for
HER2 transcripts in blood. These analyses show a gut
correlation with the ICH and FISH methods but are still not
established as a diagnostic tool [127–129].
Genomic analysis is not always the right method. To date,
no quantitative method, such as real-time PCR, has been
clinically implicated as being able to detect mRNA levels of
ESR1 (the gene encoding for the ERα)o rH E R 2o rt od e t e c t
gene amplification events for HER2 at the genomic DNA
level. In the case of ER, the reason is that the protein stability
but not the mRNA expression determines the levels of the ER
in the tumour cells and thus the ER status of the tumors [130].
In addition to such targeted approaches, microarrays now
reliably allow the simultaneous quantification of the
mRNAs of 25,000 known human genes, but also of miRNA
expression and even the identification of splice variants.
These tools may serve for the differential diagnosis of
diseases, for prognostic purposes and for the prediction of
the response to drug therapy [131–133].
The technical basis of pharmacogenetics and genomics
Clinical pharmacology depends on reliable bioanalytical
techniques and an understanding of their capabilities and
limitations. In this review we restrict our discussion to
mentioning the basic techniques of the wet and dry
laboratories of pharmacogenetics and genomics (Tables 5
and 6).
Statistics, bioinformatics and systems biology
There are almost 12 million SNPs in the human genome
[exactly 11,811,594 SNPs, of which 5,689,286 are validat-
ed SNPs, according to the last release of the database
dbSNP, build 127 (accessed March 2007): http://www.ncbi.
nlm.nih.gov/SNP/Notes/build127_announce.txt]. In the
very near future, a clinical pharmacologist will have to
deal not only with clinical and laboratory data on his/her
volunteers or patients but also with data on the patient_s
500,000 or 1 million SNPs. The cell biologist in the
laboratory will also have data data on the same number of
gene variants in the cell. And it is not only these 0.5 or 1 or
3 million SNPs, but many of these may interact – a
phenomenon known in genetics as epistasis – to generate
certain phenotypes. Consequently, an almost infinite num-
144 Eur J Clin Pharmacol (2008) 64:133–157ber of interactions will have to be considered, and the
numbers of factors and variables to be analysed in
transcriptomics, metabolomics and other broad approaches
are not smaller. These interactions may be quite complex –
partially antagonistic, partially superadditive – and they
surely will not be limited to interactions between two genes
respectively, but there will be interactions between multiple
genes. The amount of epigenetic variation is even bigger,
since the patterns differ between tissues and ages of the
individual. Thus, the development of bioinformatics and
genetic statistics plays a crucial role in the further
development of pharmacogenetics and genomics. There
are too many variations and interactions to be experimen-
tally studied, and we urgently need methods to identify
those variants which are biologically relevant.
Some approaches to identify the – potentially – most
relevant regions in the genome have already evolved and can
be further developed. Since the first interspecies comparisons
of haemoglobin, protein sequences homology search has
been an important tool to identify those segments in the
genome that are particularly crucial for the biological
function of a certain protein. Linkage of genetic variants on
the same chromosome is a central basis of methods in
genetic statistics. If a person has a certain variant at a certain
position, the same person will probably also have other
linked variants 10,000 or 50,000 bp nearby, and the same
constellation will be found in several relatives of this person.
This linkage is illustrated by red or orange rhombes in the
lower part of Fig. 4, which shows the haplotype structure at
the cytochrome P450 2C9 gene locus.
The impact of this linkage was taken into consideration
in earlier research, such as in describing genetic variation in
cytochrome P450 variants [136], and it has been expanded
to a genome-wide approach with the human haplotype map
project [90]( www.hapmap.org). It has become apparent
that there are recombination hotspots and haplotype blocks,
i.e. regions of tight linkage, as indicated by the large,
almost entirely red triangular regions in Fig. 5. Knowledge
about such linkage may greatly facilitate genotyping since
from all completely linked polymorphisms only one has to
be analysed. One can concentrate on the so-called tagging
SNPs and still know a lot about all of the variants because
all the other variants are linked. Based on a selection of
typed variants, it is possible to input a larger number of
variants into each individual_s genome and thereby have a
very high density map of genetic markers [137].
While the variants are arranged in the chromosomes in a
linear chain, we now recognize them as being arranged in so-
called haplotype blocks within which there are dozens,
hundreds or even thousands of variants relatively tightly
Table 5 Important basic techniques for genotype analysis in pharmacogenetics and genomics
Method Short description and purpose
Sanger dideoxy (end terminal) sequencing Reading of DNA sequences, identification of new polymorphisms
Denaturing high performance liquid
chromatography (DHPLC)
Variant and wild-type DNA forms differently shaped hybrid molecules (homoduplex versus
heteroduplex) which can be separated by ion-pair reverse phase HPLC to identify
polymorphisms.
PCR-RFLP The polymorphic genomic region is amplified by PCR and cut by sequence-specific enzymes
(restriction endonucleases). The resulting fragments are analysed by electrophoresis and are
indicative of the genotypes.
Pyrosequencing A method of DNA sequencing based on the sequencing by synthesis principle [134]. Used in SNP
genotyping and DNA methylation analyses. The principle behind this method is also the basis of
the current large-scale DNA sequencing known as 454 “next generation” [135] capable of
sequencing more than 100 million basepairs per day.
Single-base (primer) extension (also known
as mini-sequencing)
Short oligonucleotides are annealed so that their 3’-end directly upstream the polymorphic site.
Elongation of only one single base is performed by using a mixture of (fluorescently labeled)
ddNTPs without dNTPs. The products can be detected either with sequencing or using MALDI-
TOF detection system. Used as multiplex reaction in the SNPs genotyping
DNA microarrays Microarray solid-phase bound DNA molecules to simultaneously genotype large numbers of SNPs
(up to more than a million) in a single sample. Used in the genome-wide association studies.
RNA/cDNA microarrays Used in gene expression analyses by quantify amounts of transcripts in a single sample or in
comparison between two samples. Useful for the quantification of big number of different
transcripts (also genome-wide) in single samples.
PCR PCR, basic technique in almost all current pharmacogenetic and genomic analysis
qPCR (real-time PCR) Detection of the PCR product formation while PCR reaction proceeds using various fluorescence
quenching (TaqMan®) or fluorescence energy transfer (Light-Cycler®) techniques for
genotyping of single SNPs in many samples.
qRT-PCR (quantitative reverse transcriptase
PCR)
Used to quantify amounts of transcripts in a sample after a reverse transcription reaction. Useful
for quantification of RNAs in big numbers of samples.
Eur J Clin Pharmacol (2008) 64:133–157 145Fig. 5 Illustration of gene arrangement and haplotype structure of the
CYP2C gene locus viewed by the HapMap database. The 480,000-bp
region from the long arm of chromosome 10 shown here includes the
genes CYP2C18, CYP2C19, CYP2C8 and CYP2C8 (shown as yellow
arrows in the middle). The linkage disequilibrium (LD) pattern of the
546 SNPs recorded in the HapMap database and located in this is
shown as red-coloured rhombes at the bottom of the picture. The
depth of the red colour indicates the strength of the pairwise LD,
varying from deep red for full LD (D'=1) to white for no LD existing
(D’=0). The picture is produced using HapMap database (www.
hapmap.org,[ 90, 138]) and the HAPLOVIEW software [139]
Fig. 4 Relationship between genomic variation, variation in RNA and protein expression and the biological effects and clinical effects. Some –
but not all – mechanisms of regulation are also indicated
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blocks there is only relatively sparse linkage. Systematic
analysis of the length of the specific linkage blocks may be
informative in terms of the functional and evolutionary role
of specific variants and haplotypes. An extended haplotype
homozygosity is considered to indicate those variants which
are selected in recent evolution. Thus, this analysis may
greatly help to identify the really important variants among
the more than 12 million SNPs in the human genome.
However, as yet there is no convincing prospective valida-
tion of this approach (Table 6).
It is immediately evident that disease risk and response
to drugs may depend on the combinations of several genes,
and years ago scientists and companies emerged with the
concept to sell predictive marker combinations. However, it
is all too easy to identify in each study predictive marker
combinations which are more predictive than the single
markers alone. The aim, however, is to identify predictive
marker combinations which remain predictive beyond the
study in which they were identified.
Predictive marker combinations may be identified as
interaction terms in cross-tabulations, analyses of variance or
logistic regression analyses, and data mining tools, such as
recursive partitioning, are particularly helpful for this. The
situations in which such recursive partitioning should be
performedinwholegenomescansisnotyetclear:intheentire
data sets or, as some authors have performed [140], in subsets
identified in a monofactorial analysis as possible risk factors.
Hypothesis-free genome-wide association studies
Disease risk studies
The vast majority of pharmacogenetic studies that have been
completed thus for used the so called the candidate gene
approach. That means that those genes were analyzed from
which the investigators assumed that they may be relevant
according to biological reasoning. The alternative, genome-
wide linkage analysis, was only rarely applied in pharmaco-
genetics. This approach was successfully applied in linkage
Table 6 Bioinformatics databases and software tools for pharmacogenetics and genomics
Aim Computer solution Website
Databases
Human genome National Center for Biotechnology
Information in USA (NCBI)
www.ncbi.nlm.nih.gov/genome/guide/human/
Ensembl www.ensembl.org/Homo_sapiens/
SNP databases dbSNP at NCBI www.ncbi.nlm.nih.gov/SNP/
Japan database JSNP http://snp.ims.u-tokyo.ac.jp/
Pairwise linkage disequilibrium
and haplotypes
HapMap project www.hapmap.org
Gene expression analysis Gene Expression Omnibus (GEO) by
NCBI
www.ncbi.nlm.nih.gov/geo/
Metabolic pathways Kyoto Encyclopedia of Genes and
Genomes (KEGG)
www.genome.jp/kegg/
Software
Homology search BLAST at NCBI www.ncbi.nlm.nih.gov/BLAST/
Sequence alignment and
identification of new SNPs
Gap4 (part of Staden package) http://staden.sourceforge.net/
Haplotype mapping (phasing) Phase, Fastphase http://stephenslab.uchicago.edu/software.html (there is also a
new program for imputation of analyzed to in-silico linked
SNPs)
Pairwise linkage disequilibrium
and visualization of Haplotype
blocks
Haploview www.broad.mit.edu/mpg/haploview/
Extended haplotype homozygosity
(EHH)
Sweep www.broad.mit.edu/mpg/sweep/
Analysis of SNPs affecting
promoter function
TRANSFAC http://transfac.bioinf.med.uni-goettingen.de/
Analysis of SNPs affecting splice
sites and ESEs
Automated Splice Site Analyses
(Children_s Mercy Hospitals
Missouri, USA)
https://splice.cmh.edu/
ESEfinder 3.0 (Cold Spring Harbor
Laboratory)
http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?
process=home
Eur J Clin Pharmacol (2008) 64:133–157 147studies of families to map the causal mutation for many
mono-genetic diseases, and sets of several hundreds of
genome-wide VNTR markers were sufficient to identify loci
such as the BRCA1 locus or the cystic fibrosis gene locus.
The approach of a genome-wide association study of
unrelated individuals started only very recently to become a
successful approach in identifying medically relevant poly-
morphisms. That approach became successful after inves-
tigators became technically able to genotype sufficient
numbers of single nucleotide polymorphisms and subjects
[141]. Even the first genome-wide microarrays probing
“only” 10,000 SNPs may be useful in family studies, but
we are not aware of a successful application in association
studies with unrelated cases and controls. Microarrays
probing for 500,000 or 1,000,000 SNP markers equally
distributed in a single human genome now enable such
studies. A more economic approach appears to be that of
testing for haplotype-tagging SNPs, and several studies
(Table 7) have used this approach with 300,000 haplotype-
tagging SNPs.
One of the first success stories of genome-wide SNP
analysis was the identification of the complement factor H
(CFH) His402Tyr polymorphisms as the susceptibility
factor for macula degeneration with an odds ratio above 7
for homozygous carriers of the variant [142]. This study
comprised only 96 cases, and 50 controls, who were
analysed for 116,204 SNPs; the results were subsequently
confirmed by two other studies and are in agreement with
linkage data of the locus obtained earlier in family studies
[143–146]. A similar story proving the success of genome-
wide association studies is the identification of the genetic
polymorphism underlying a frequent subtype of open-angle
glaucoma, the so-called exfoliation glaucoma [147] and
gallstone disease. According to this data, a certain haplo-
type from two non-synonymous variants in the gene or a
single SNP conferred more than a 30-fold and sevenfold
increased risk for the disease, respectively [148]. Unfortu-
nately, these cases are not representative of other multifac-
torial diseases, and odds ratios of 7 or 30 for single genes
cannot typically be expected in polygenetic diseases.
However, odds ratios between 1.0 and 2.0 found in
many recently published genome-wide association studies
(Table 7) raise a number of questions concerning the causal
relationship behind these findings and concerning the
medical relevance of these findings.
Some genome-wide analyses of polygenetic disease are
summarized in Table 7 [140, 148, 151, 154, 156, 157]. The
largest study included 14,000 patients suffering from seven
diseases and 3000 common controls [156]. The study was
planned to have sufficient power to detect associations with
an odds ratio as low as 1.5, and these studies suggested a
number of previously unknown and unexpected susceptibil-
ity loci and susceptibility genes (Table 7). Most interestingly,
some of the identified susceptibility loci were common for
different diseases, indicating a common etiology [151, 156–
158]. As seen in column 2 of Table 7, a most important
priority in many of the genome-wide association studies was
to obtain as many subjects as possible, apparently to avoid
the risk of a too low power. However, study design issues are
not less important than statistical power to terms of obtaining
reliable and reproducible data [159, 160].
In addition, several general questions regarding these
types of analyses have been addressed. Most importantly, a
replication strategy became almost standard in these studies
[161], which was probably the lesson also learned from
studies carried out 20 years which obtained many irrepro-
ducible data in pharmacogenetic and genomic disease
association research. The ability to replicate is the essential
step justifying further work on the finding, but it does not
exclude some types of systematic error. In addition, at least
as important as the false positive data are the false negative
data, and the number of truly medically relevant gene
variant not identified in studies, such as those listed in
Table 7, may be quite large although we cannot precisely
calculate this amount of false negative findings. Replication
or lack of replication of gene-disease association data is a
central open question in this type of research. Reasons
behind this include unresolved multiple testing issues but
also complex gene-gene and gene-environment interaction
which may differ depending on ethnicity, time-frame,
location of the study and many other factors.
It is interesting to note that a number of significant loci
were ultimately identified in almost all studies. Neverthe-
less, we would not consider genome-wide association
studies as the recipe of guaranteed success. Because of
the known phenomenon of publication bias, we cannot
assume that all such genome-wide studies with sufficient
power are publicly available. It is notable, however, that
there was one negative sub-study listed in Table 7. As the
authors noted, there were no signals with significance
below 5×10
−7, but there were multiple signals with p
between 10
−4 and 10
−7. The authors explained the failure to
find a significant association in their study by a study
design that was not optimal for hypertension, by still
existing limitations of the tested variants and by possible
multifactorial causation of hypertension which cannot yet
be uncovered by the applied approaches [149].
As indicated in Table 7, many of the odds ratios
identified in genome-wide association studies for specific
diseases were far too small to be relevant for individual
decision-making in the therapy of patients but may give
new insights into the diseases. Thus far, most genome-wide
analyses have dichotomized their dependent variable into
cases and controls, which may result in a significant loss of
power and particularly for phenotypes related to drug
dosage quantitative trait analyses are needed.
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Disease Sample size N
cases/controls
Technique
a Locus (gene)
identified
Polymorphism
identified
PNSG
b Odds ratio (95%
confidence intervals)
c
References
Bipolar
disorder
1868/2938 A500k 16p12 rs420259 Yes 2.07 (1.6–2.69) [149]
Coronary
artery disease
1926/2938 A500k 9p21 rs1333049 No 1.90 (1.61–2.24) [149]
Crohn’s
disease
1748/2938 A500k NOD2 rs17221417 Yes 1.92 (1.58–2.34) [149]
IL23R rs11209026 Yes 1.86 (1.54–2.24)
2q37 rs10210302 No 1.85 (1.56–2.21)
BSN rs9858542 No 1.84 (1.49–2.26)
5p13.1 rs17234657 No 2.32 (1.59–3.39)
IRGM rs1000113 No 1.92 (0.92–4.00)
10q21 rs10761659 No 1.55 (1.3–1.84)
NKX2-3 rs10883365 No 1.62 (1.37–1.92)
16q12 rs17221417 No 1.92 (1.58–2.34)
PTPN2 rs2542151 No 2.01 (1.46–2.76)
Hypertension 1952/2938 A500k None [149]
Rheumatoid
arthritis
1860/2938 A500k PTPN22 rs6679677 Yes 3.32 (1.93–5.69) [149]
HLA-DRB1 rs6457617 Yes 5.21 (4.31–6.30)
7q32 rs11761231 No 1.64 (1.35–1.99)
Type 1
diabetes
1963/2938 A500k PTPN22 rs6679677 Yes 5.19 (3.15–8.55) [149]
HLA-DRB1 rs9272346 Yes 18.5 (12.7–27.0)
12q13 rs11171739 No 1.75 (1.48–2.06)
12q24 rs17696736 No 1.94 (1.65–2.29)
PTPN2 rs12708716 No 1.55 (1.27–1.89)
Type 2
diabetes
1924/2938 A500k TCF7L2 rs4506565 Yes 1.88 (1.56–2.27) [149]
CDKAL1 rs9465871 No 2.17 (1.60–2.95)
FTO rs9939609 No 1.55 (1.30–1.84)
Gallstone
disease
2113 /1965
d A500k ABCG8 rs11887534
(D19H)
Yes 7.10 (0.90–158.6) [148]
Myocardial
Infarction
4587/12767
d IH300k 9p21 rs10757278 No 1.64 (1.47–1.82) [150]
Atrial
fibrillation
2801/17714
d IH300k 4p25 rs2200733 1.68 (1.53–1.83)
e [151]
Type 2
diabetes
2376/2432
d IH300k PPARG rs1801282 Yes 1.20 (1.07–1.33) [140]
SLC30A8 rs13266634 Yes 1.18 (1.09–1.29)
HHEX rs1111875 Yes 1.10 (1.01–1.19)
TCF7L2 rs7903146 Yes 1.34 (1.21–1.49)
KCNJ11 rs5219 Yes 1.11 (1.02–1.21)
IGF2BP2 rs4402960 No 1.18 (1.08–1.28)
CDKAL1 rs7754840 No 1.12 (1.03–1.22)
9p21 rs10811661 No 1.20 (1.07–1.36)
Chr11 rs9300039 No 1.48 (1.28–1.71)
FTO rs8050136 No 1.11 (1.02–1.20)
e
Type 2
diabetes
6529/7252
d A500k SLC30A8 rs13266634 Yes 1.07 (1.00–1.16) [152]
HHEX rs1111875 Yes 1.14 (1.06–1.22)
TCF7L2 rs7903146 Yes 1.38 (1.31–1.46)
KCNJ11 rs5219 Yes 1.15 (1.09–1.21)
PPARG rs1801282 Yes 1.09 (1.01–1.16)
9p21 rs10811661 No 1.20 (1.12–1.28)
IGF2BP2 rs4402960 No 1.17 (1.11–1.23)
CDKAL1 rs7754840 No 1.08 (1.03–1.14)
e
Rheumatoid
arthritis
1522/1850 IH300
IH550
TRAF1 rs3761847 No 1.32 (1.23–1.42)
e [153]
Exfoliation
Glaucoma
290/14672
d IH300 LOXL1 rs1048661+
rs3825942
No 27.05 (14.9–49.2) [147]
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The genome-wide disease association studies may provide
important hints for planning the next generation of clinical
pharmacogenomic studies in which we want to identify
genomic markers predicting therapy response or adverse
events. A number of issues have to be carefully considered
here. One problem in many drug response studies (but
mostly not in studies on adverse drug events) is the ability
to distinguish between drug response and different forms of
the natural course of the disease. This is a particular
problem in diseases with a naturally variable course, such
as ulcer or depression. The only formally correct solution
would be to compare episodes without treatment with
treatment episodes within individuals, but this is ethically
not possible. A comparison of response to differently acting
treatments might reveal important insights.
Where should we go?
After more than 40 years of pharmacogenetic and pharma-
cogenomic research, we now have a multitude of options.
The highlights of the year 2007 were numerous large
genome-wide association studies, and data obtained from
some of these studies will result in optimized medical
therapies. However, more than before, pharmacogenetics
and genomics research remains an iterative process (Fig. 6),
and there is much room for opportunities for improvement
in each of the approaches. Viewed from the perspective of
clinical pharmacologist, research should start with a well-
defined and well-designed clinical study and should finally
end with improvements for the patients.
However, between the start and the end we have to apply
a lot of molecular and information sciences. A constant
pattern in pharmacogenetic research from early CYP2D6–
cancer association studies to recent genome-wide associa-
tion studies is that genetic polymorphisms apparently
correlate with medical phenotypes, but it remains obscure
precisely how the polymorphisms may do that. So there is a
demand to distinguish between those associations which are
true and leading to definitive results and those which are
not – and we have to elucidate the underlying mechanisms.
As yet, this demand has not been met.
To this end, human pharmacology studies are well
suited, but ex vivo research using human cells can also be
applied. For example, cell lines from genetically unrelated
individuals representing different organs and tissues may
significantly help in the functional validation of SNPs
identified in clinical genetic-phenotypic association studies
[162]. Lymphoblastoid cell lines and fibroblasts from the
participants of the HapMap Project, which are already
genotyped for more than 4,000,000 SNPs (Coriell cell
repositories, http://ccr.coriell.org/) are nowadays worldwide
in use to do just such research. In contrast to experiments
with primary cells, these cells enable repetitive measure-
ments with all of the different genotypes at the same time
and with greatly improved possibilities for inter-laboratory
validation. Of course, there are also limitations due to
artifacts that potentially arise from cell culture or from
immortalization procedures, and other cell types are
needed, but the principle is moving forward. Without
having been spectacularly new in the public mind, in vitro
approaches nevertheless have already significantly changed
clinical pharmacology. For example, drug–drug interactions
can not be quite precisely predicted based on in vitro drug
metabolism studies, and clinical proband studies are more a
final confirmation rather than an initial search, as it was
40 years ago. Similar approaches are developing in drug
transporter research and in pharmacodynamics research
concerning intended and adverse drug effects, such as long-
QT producing effects at the HERG (KCNH2) channel [163]
(Table 8).
Table 7 (continued)
Disease Sample size N
cases/controls
Technique
a Locus (gene)
identified
Polymorphism
identified
PNSG
b Odds ratio (95%
confidence intervals)
c
References
Breast cancer 4398/4316
d Custom
array
FGFR2 rs2981582 No 1.63 (1.52–1.72) [154]
TNRC9 rs12443620 No 1.23 (1.17–1.30)
TNRC9 rs8051542 No 1.19 (1.12–1.27)
MAP3K1 rs889312 No 1.27 (1.19–1.36)
LSP1 rs3817198 No 1.17 (1.08–1.25)
H19 rs2107425 No 0.95 (0.89–1.01)
8q rs13281615 No 1.18 (1.10–1.25)
Colorectal
cancer
7334/5246
d IH550 8q24 rs6983267 1.47 (1.34–1.62) [155]
aA, Affymetrix; IH, illumina haplotype tagging array
bPreviously known susceptibility gene or locus
cUnless mentioned otherwise, all odds ratios refer to the relative risks of homozygous variant carriers compared to homozygous wild-type carriers
dInitial genome-wide screens were performed only with a subset of the sample sizes given here for the final analysis
eOdds ratio for the presence versus absence of risk allele (allelic odds ratio)
150 Eur J Clin Pharmacol (2008) 64:133–157Fig. 6 The pathways of pharmacogenetic and pharmacogenomic
research. The routes shown here may not be the only ones, but the
figure should illustrate how multiple approaches have to be combined
to obtain pharmacogenomic knowledge that is of value for the
development of new therapeutics or for the improvement of existing
therapies
Table 8 Theses summarizing the present review
Drug effects
1. If the safety or efficacy of a drug may depend on genetic polymorphisms, the best choices are either to delete the drug from the market or to
analyse and consider the genetic polymorphism in therapy.
2. Pharmacogenetics and genomics are a most important reason behind interethnic differences in drug effects. Thus, pharmacogenetics has to
be carefully studied in worldwide marketing of drugs and in pharmacovigilance
3. Many pharmacogenetic polymorphisms may have both positive and negative consequences for human health depending on the context and
exposures
4. Applying pharmacogenetic knowledge in the clinics should not always mean applying genotyping, often some type of phenotyping may be
superior (e.g. concerning G6PDH, BCHE, TPMT, DPD).
5. Every clinical pharmacologist should know about the background and clinical consequences of genetic polymorphisms in G6PDH, BCHE,
NAT2, CYP2D6, CYP2C19, CYP2C9, TPMT, DPD, UGT1A1, VKORC1 and factor V; very soon that list may have to be updated.
6. As with many complex and new technologies, there are problems and delays in the transfer of scientific pharmacogenetic knowledge to the
bedside. Specific translational research has to be supported.
7. Prospective evaluation studies on the clinical value of pharmacogenetic diagnostics are needed to proof the concept of pharmacogenetic
diagnostics. But in many areas of drug therapy such studies are not feasible; in such cases, the pharmacogenetic diagnostics will have to
be based on scientifically valid mechanistic reasoning and appropriate clinical monitoring.
8. In addition to concentrating on single genes, pharmacogenetic and genomic pathway research is required to understand the causes behind
pharmacokinetic and pharmacodynamic inter-individual variation.
9. Because of the mass of pharmacogenetic information, medical information technologies including bioinformatics are essential in the future
of clinical pharmacology and clinical pharmacogenetics.
10. Besides the traditional axis between genes - mRNAs - proteins and functions, other mechanisms, such as epigenetics and RNAi, are
apparently relevant for understanding of interindividual variation in drug effects and adverse effects.
11. SNP-based genome-wide association studies have proven their value, and new insights have been obtained for instance concerning
gallstone disease, open angle glaucoma and macula degeneration.
12. The future of pharmacogenetic and genomic research will be a mixture of genome-wide SNP and expression analysis in appropriately
designed clinical studies,andthis willhaveto becombinedwith invitro andexvivopharmacogenomic research withhumancells andmodel
organisms and with human pharmacological research. Finding the right combination of research tools may be the most important demand.
Eur J Clin Pharmacol (2008) 64:133–157 151In terms of research priorities, genetically determined
aberrations in signal transduction pathways may be most
exciting new option, and these have already been identified
in many types of cancer. However, thus far there is only
relatively little data on the impact of frequently inherited
polymorphisms in intracellular signal transduction path-
ways. Apparently, despite the requirements for professional
specialization, a combined view on genomics, transcrip-
tomics, proteomics, epigenomics, metabolics and clinical
requirements [164] is needed.
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